首页> 美国卫生研究院文献>Journal of Psychiatry Neuroscience : JPN >Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III randomized double-blind fixed-dose placebo-controlled study

【2h】

Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III randomized double-blind fixed-dose placebo-controlled study

机译：患有严重抑郁症的左旋米那普仑ER 40 mg和80 mg：III期随机双盲固定剂量安慰剂对照研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundMajor depressive disorder (MDD) is a global health concern. This study examined the efficacy, safety and tolerability of an extended-release (ER) formulation of levomilnacipran, an antidepressant approved for the treatment of MDD in adults.

机译：背景重大抑郁症（MDD）是全球性的健康问题。这项研究检查了左旋米那普仑的缓释（ER）制剂的功效，安全性和耐受性，左旋米那普仑是一种批准用于成人MDD治疗的抗抑郁药。

著录项

期刊名称 Journal of Psychiatry Neuroscience : JPN
作者
David Bakish; Anjana Bose; Carl Gommoll; Changzheng Chen; Rene Nunez; William M. Greenberg; Michael Liebowitz; Arif Khan;
展开▼
作者单位

展开▼
年(卷),期 2014(39),1
年度 2014
页码 40–49
总页数 10
原文格式 PDF
正文语种
中图分类神经科学;精神病学;
关键词

相似文献

外文文献
中文文献
专利

1. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: A phase III, randomized, double-blind, fixed-dose, placebo-controlled study [J] . BakishD., BoseA., GommollC., Journal of psychiatry & neuroscience: JPN . 2014,第1期

机译：患有严重抑郁症的左旋米那普仑ER 40 mg和80 mg：III期，随机，双盲，固定剂量，安慰剂对照研究
2. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: A phase 3, randomized, double-blind, placebo-controlled study [J] . AsnisG.M., BoseA., GommollC.P., The journal of clinical psychiatry . 2013,第3期

机译：左旋米那普仑在重大抑郁症中持续释放40 mg，80 mg或120 mg的功效和安全性：一项3期，随机，双盲，安慰剂对照研究
3. A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120?mg/day) in patients with major depressive disorder [J] . Carl P. Gommoll, William M. Greenberg, Changzheng Chen Journal of Drug Assessment . 2014,第1期

机译：轻度重度抑郁症患者左旋米那普仑ER（40–120？mg /天）的弹性剂量的随机，双盲，安慰剂对照研究
4. MULTI-CENTER, PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED STUDY OF ORAL TOCERANIB PHOSPHATE (PALLADIATM, SU11654), A RECEPTOR TYROSINE KINASE INHIBITOR, FOR THE TREATMENT OF DOGS WITH RECURRENT MAS [C] . Cheryl L London, Carolyn J Henry, Anthony W Rusk, Annual conference of the Veterinary Cancer Society . 2008

机译：多中心，安慰剂对照，双盲，随机研究口服Toceranib磷酸盐（Palladia TM，SU11654），受体酪氨酸激酶抑制剂，用于治疗经常性MAS的狗
5. A Randomized, Double-Blind, Placebo-Controlled Crossover Trial Evaluating the Effect of Intranasal Insulin on Cognition and Emotional Processing in Individuals with Treatment-Resistant Major Depressive Disorder. [D] . Cha, Danielle Soh-Young. 2016

机译：一项随机，双盲，安慰剂对照的交叉试验评估了鼻内胰岛素对难治性重度抑郁症患者认知和情绪加工的影响。
6. A randomized double-blind placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder [O] . Carl P. Gommoll, William M. Greenberg, Changzheng Chen 2014

机译：轻度重度抑郁症患者左旋米那普仑ER剂量（40-120μmg/天）的随机双盲安慰剂对照研究
7. A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder [O] . Carl P. Gommoll, William M. Greenberg, Changzheng Chen 2014

机译：主要抑郁症患者柔性剂量脐带氏菌（40-120 mg /天）的随机，双盲，安慰剂对照研究

Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III randomized double-blind fixed-dose placebo-controlled study

摘要

著录项

相似文献

相关主题

期刊订阅